Tagged with France,

France Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial investments exceeding EUR 2.3 billion, the establishment of France as a global manufacturing hub for next-generation diabetes and obesity treatments,…

France France is betting big on industrial transformation. With its sweeping EUR 54 billion France 2030 investment plan, the government has laid down a clear ambition: to become a global leader in innovation and industrial competitiveness. While foreign investment is flowing in, and biomedicine production is robust, local pharma industry leaders…

Denmark As European biotech continues to navigate tightening capital markets and increasing global competition, Kurma Partners is doubling down on its core belief: that world-class innovation can, and should, be built and scaled from within Europe. Managing Partner Rémi Droller shares how Kurma’s investment model combines early-stage company creation with long-term…

Global As the global population ages and the incidence of vision-related conditions rises, ophthalmology is entering a transformative era. Beyond symptom management, the field is moving towards disease modification through cell and gene therapies like optogenetics while boosting artificial intelligence (AI) to speed up pipelines, and developing minimally invasive delivery systems…

France Serge Picaud, the Executive Director of the Paris Vision Institute outlines a bold vision to transform ophthalmology through cutting-edge research and innovation. From pioneering the first successful optogenetic vision restoration to advancing therapies for AMD, myopia, and diabetic retinopathy, the institute blends academic excellence with commercial impact supported by 15…

France Thomas Courbe, Director General for Enterprise at the French Ministry of Economy and Finance, has led France’s industrial transformation since 2019. He oversees, within the EURO 54 billion France 2030 plan, reforms in manufacturing, decarbonisation, and digital innovation. Under his leadership, France has become a top destination for foreign investment,…

France Julien Ettersperger, appointed in November 2023 as the first internal leader of Medicen, is steering the agency through a strategic transformation to establish Île-de-France as Europe’s leading health innovation hub. Leveraging the region’s dense research capacity, he champions stronger public-private collaboration to better convert scientific excellence into commercial impact. The…

France The top 10 companies in the French retail generics market for 2024 according to Smart Pharma Consulting’s insights on the French pharma market. Last year, Viatris and Biogaran generated more than EUR 2.9 billion in sales and, taken together, represented over half of the total French retail generic market in…

France Professor Bana Jabri, Director of the Institut Imagine, brings a transatlantic perspective to advancing genetic medicine. After 25 years in the US, she now leads efforts in France to harness genomic technologies, foster interdisciplinary collaboration, and modernise academic–industry partnerships. Her vision calls for strategic investment, institutional autonomy, and greater risk…

France As global powers race to secure health sovereignty and industrial resilience, France stands at a crossroads. With rising regulatory asymmetries, fierce international competition, and mounting fiscal pressure on its pharmaceutical sector, the stakes have never been higher. Didier Véron, President of G5 Santé – the collective voice of France’s leading…

France France is experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer committing over EUR 4 billion in new investments since 2023. This wave of capital represents more than just expansion – it signals a broader pivot toward European pharmaceutical independence and potentially…

France The biggest recent stories from French healthcare and the life sciences, including Sanofi’s deal to buy immunology biotech Blueprint; the largest from a European pharma this year. Elsewhere Servier is snapping up a experimental leukaemia treatment from China, while French tech firm OWKIN is touting a new “AI-powered research co-pilot”…